Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Garetosmab

Stage Phase 2Stale

Sponsor Regeneron Pharmaceuticals

Route injection

Class Myostatin/activin

Mechanism activin A-blocking antibody

Sources

registry, as of 2026-09-01Stale

https://clinicaltrials.gov/study/NCT06299098

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 1005. Conditions Obesity. This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the

ClinicalTrials.gov NCT06299098 protocol and results modules

registry, as of 2025-09-17Stale

https://clinicaltrials.gov/study/NCT06970405

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women. Overall status WITHDRAWN. Phases PHASE1. Lead sponsor Regeneron Pharmaceuticals. Enrollment 0. Conditions Obesity. This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other res

ClinicalTrials.gov NCT06970405 protocol and results modules

publication, as of 2023-10-23Stale

https://pubmed.ncbi.nlm.nih.gov/37770652/

flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo (n = 24) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; n = 43). The primary end points were s

PMID 37770652

Studies

COURAGE

Registry NCT06299098

Phase Phase 2

Status Active, not recruiting

Enrollment 1005

Start 2024-03-13

Primary completion 2026-06-16

Study completion 2026-10-21

Catalyst Primary completion. 2026-06-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo

Population Obesity

Trevogrumab

Comparator placebo

Population Obesity

Arm A0

Comparator placebo

Population Obesity

Arm A1

Comparator placebo

Population Obesity

Arm B0

Comparator placebo

Population Obesity

Arm B1

Comparator placebo

Population Obesity

Arm C0

Comparator placebo

Population Obesity

Arm C1

Comparator placebo

Population Obesity

Arm D0

Comparator placebo

Population Obesity

Arm D1

Comparator placebo

Population Obesity

Arm 1

Comparator placebo

Population Obesity

Arm 2

Comparator placebo

Population Obesity

Arm 3

Comparator placebo

Population Obesity

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Registry NCT06970405

Phase Phase 1

Status Withdrawn

Enrollment 0

Start 2025-05-29

Primary completion 2026-06-08

Study completion 2026-06-08

Catalyst Primary completion. 2026-06-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

High Dose

Comparator placebo

Population Obesity

Low Dose

Comparator placebo

Population Obesity

Placebo

Population Obesity